Andersons pediatric cardiology 2382
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (78.96 KB, 3 trang )
ethicalconsiderationsandfuturedirectionsfor,1540
genotype,1539–1540,1540t
phenotype,1539,1540f
Suddendeath,reducing,inchronicheartfailure,1202–1203,1202f,1203t
Suiciderightventricle,indiagnosticcatheterization,247
Superiorcavalvein,anomaliesof,462–469,462f–463f
absentbilaterallyof,463
absentrightsuperiorcavalveinas,462–463
intra-atrialleftsuperiorcavalveinas,469
leftsuperiorcavalvein
connectedtomorphologicallyleftatrium,464–465
tocoronarysinus,462,462f
drainingtoleftatriumas,467
retro-aorticbrachiocephalicvein,469,469f
rightsuperiorcavalveindrainingtoleftatriumas,465–466,466f
systemicvenousreturn,468
Superiorcavopulmonaryconnection,1296–1300,1296b,1315–1316
decisionmakingin,1297–1298
infunctionallyuniventricularheart,1266–1267,1266f–1267f
postoperativeconsiderationsin,1298–1300,1298b
bedsidepreparedness,1298
commonfindings,1299
familysupportandinterstageIIsurveillanceandmonitoring,1300
invasiveandnoninvasivemonitoring,1298
management,1298–1299
pleuraleffusionsandchylothorax,1299
sinusnodedysfunction/arrhythmia,1299
preoperativeevaluationof,1296,1296t
surgicalstrategiesfor,1296–1297,1296f–1297f
Superiorvenacava,indiagnosticcatheterization,244,245f
Superoinferiorventricles,920–926
Supplementaryoxygenation,fetal,144–147
acuteandchroniccardiovasculareffectsof,144–145
prognosticuseof,145–147,146f
Supravalvarmitralring,614,615f
Supraventriculararrhythmias,341–349
Supraventriculartachyarrhythmias
antiarrhythmicfetaltreatmentfor,137–141
perinatalmanagementof,138
pharmacotherapyfor,138–140
therapeuticuseof,147
Supraventriculartachycardia(SVT),341,341f
afterheartsurgery,375–378
catheterablationfor,345–346
medicalmanagementof,345
neonatal/infant,naturalhistoryof,345
recurrent,341–342,342f
reentrant,managementof,345,346f
Surgery
forcongenitallymalformedhearts,210
forFontanfailure,1346–1347
foruniventricularheart,1350
Surgicalligation,forprematurity,199–200
postoperativecareof,200
postoperativecomplicationsof,199–200,200f
Surgicalshunts,stentingof,275–276
Surgicaltechniques,215–235
approachestotheheart,215–220
minimallyinvasive,218–219,219f
opensternumand,219–220
sternotomyas,215–217,216f–217f
thoracotomyas,217–218,217f–219f
materialsfor,220–225
patchmaterialfor,220–221
suturesfor,220
valvelessconduitsfor,220–221
valvesfor,221–225
homograft,222,222f
mechanical,221–222,221f
pulmonaryautograft,223
repair,225
selectionof,223–225,224f
xenobioprosthetic,222,222f
SurgicallyimplantedRV-PAconduits,infectiveendocarditison,1058,1058t
Surrogatedecisionmaker(SDM),1469t
Survivalanalysis,414–415
Suturelessrepairtechnique,488
Sutures,220
SVHs,Singleventriclehearts
SVT,Supraventriculartachycardia
Swallowingdysfunction,oralintakeand,1501
SwedishNationalRegistryforCongenitalHeartDisease,1511t–1514t
SwissNationalRegistryofGrownUpCongenitalHeartDisease,1511t–1514t
Sydenhamchorea,inrheumaticfever,1009–1010
treatmentof,1017–1018
Sympatheticnervoussystem,inchronicheartfailure,1198
Sympatheticvasoconstrictorfibers,1359
β-Sympathomimeticagents,forantibody-mediatedfetalheartdisease,144
Symptomatictreatment,forhemodynamicallysignificantarterialduct,199
Syncope,340–341,341t
pacingfor,366
Syncytiotrophoblast,157–158
Syndromicmutations,52–53
Systemicarterialdysfunction,1370–1375
age-relatedevolutionof,1370
cardiovascularriskfactorsand,1371
childhoodvasculitidesand,1372–1373
clinicalimplicationsof,1375
congenitalheartdiseaseand,1373–1374
